Previous 10 | Next 10 |
2023-04-17 10:02:16 ET Gainers: Prometheus Biosciences ( RXDX ) +69% . CNS Pharmaceuticals ( CNSP ) +53% . Revelation Biosciences ( REVB ) +29% . Windtree Therapeutics ( WINT ) +26% . Kiromic BioPharma ( KRBP ) +22% . Loser...
2023-04-17 08:21:00 ET CNS Pharmaceuticals ( CNSP ) +72% . Presto Automation ( PRST ) +55% . Prometheus Biosciences ( RXDX ) +70% soars 70%, Merck dips after ~$11B buyout deal. Dragonfly Energy ( DFLI ) +49% . Kiromic BioPharma ( ...
2023-04-06 10:02:19 ET Gainers: Bullfrog AI ( BFRG ) +16% . HUTCHMED (China) ( HCM ) +10% . Aprea Therapeutics ( APRE ) +8% . Clearside Biomedical ( CLSD ) +5% . Soleno Therapeutics ( SLNO ) +5% . Losers: Scilex ( SCLX ...
2023-04-04 12:51:54 ET Gainers: Cardlytics ( CDLX ) +62% . Assure Holdings ( IONM ) +56% . The NFT Gaming Company ( NFTG ) +42% . Bullfrog AI Holdings ( BFRG ) +32% . Bellerophon Therapeutics ( BLPH ) +27% . Austin Gold ( A...
2023-04-03 13:44:04 ET Kiromic BioPharma ( NASDAQ: KRBP ) stock rose ~5% on Monday after company said it submitted an investigational new drug (IND) application to the U.S. Food and Drug Administration (FDA) to start a phase 1 of KB-GDT-01 (Deltacel), in combination with an an...
Deltacel is Being Developed as an Allogeneic, Non-Viral, Non-Engineered Off-the-Shelf Gamma Delta T-Cell Therapy Kiromic BioPharma, Inc. (NASDAQ: KRBP) (“Kiromic” or the “Company”), a clinical-stage fully-integrated biotherapeutics company using its propr...
2023-03-10 16:48:25 ET Kiromic BioPharma ( NASDAQ: KRBP ) has announced that it will effect a reverse stock split of its outstanding shares of common stock at a ratio of 1-for-30 effective on March 10, 2023. Kiromic common stock will begin trading on a split-adjusted ...
Kiromic BioPharma, Inc. (NASDAQ: KRBP) (“Kiromic” or the “Company”), a clinical-stage fully-integrated biotherapeutics company using its proprietary DIAMOND® artificial intelligence and data mining platform to develop cell therapies with a focus on immune-oncolo...
2023-03-09 14:31:53 ET Penny stocks are shares of small companies with a price of less than $5 per share. These stocks are known for their high volatility and low liquidity, making them a risky investment option. However, they also offer some unique benefits and opportunities for traders an...
Favorable Safety Results are Last Component Needed to Complete the Nonclinical Module of the Company’s IND Application IND Submission and Activation of Clinical Trial Process on Track for the First Quarter and Second Quarter of this Year, Respectively Kiromic BioPharma,...
News, Short Squeeze, Breakout and More Instantly...
Kiromic BioPharma Inc. Company Name:
KRBP Stock Symbol:
NASDAQ Market:
Kiromic BioPharma Inc. Website:
Enrollment in the Expansion Phase Expected to Commence in September Deltacel Safety Confirmed at Day 30 in Trial’s Fifth Patient; Efficacy Results on this Patient Expected in August Kiromic BioPharma, Inc. (OTCQB: KRBP) (“Kiromic” or the “Company...
Follow-up Findings Show Stable Disease FDA and IRB Approve IND for a Single-Use, Single-Patient Treatment with Deltacel Fast Track Designation Request Submitted to FDA Complete Enrollment in Trial’s Second Cohort Expected in July Kiromic BioPharma, Inc. ...
Favorable Follow-up Findings Include Stable Disease and a 13% Decrease in Tumor Size Kiromic BioPharma, Inc. (OTCQB: KRBP) (“Kiromic” or the “Company”) reports favorable six-month follow-up results from the first patient enrolled in the Deltacel-01 Phase ...